Fortress Biotech, Inc.

$2.65+4.94%(+$0.13)
TickerSpark Score
79/100
Solid
80
Valuation
100
Profitability
80
Growth
84
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FBIO research report →

52-Week Range34% of range
Low $1.67
Current $2.65
High $4.53

Companywww.fortressbiotech.com

Fortress Biotech, Inc. , a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne.

CEO
Lindsay Allan Rosenwald
IPO
2011
Employees
101
HQ
Bay Harbor Islands, FL, US

Price Chart

+51.71% · this period
$4.38$3.04$1.70May 20Nov 18May 20

Valuation

Market Cap
$85.50M
P/E
0.66
P/S
1.29
P/B
0.52
EV/EBITDA
21.67
Div Yield
0.00%

Profitability

Gross Margin
64.51%
Op Margin
-84.36%
Net Margin
193.12%
ROE
163.88%
ROIC
-20.91%

Growth & Income

Revenue
$63.26M · 9.69%
Net Income
$6.82M · 114.82%
EPS
$-0.07 · 97.49%
Op Income
$-70,221,000
FCF YoY
30.90%

Performance & Tape

52W High
$4.53
52W Low
$1.67
50D MA
$2.58
200D MA
$2.94
Beta
1.16
Avg Volume
705.73K

Get TickerSpark's AI analysis on FBIO

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Apr 1, 26Jin Davidother2,967
Mar 18, 26ROSENWALD LINDSAY A MDother475,424
Mar 18, 26WEISS MICHAEL Sother475,424
Jan 1, 26Klein Dovother27,322
Jan 1, 26Harvey Jimmieother27,322
Jan 1, 26Lorenz Kevinother27,322
Jan 1, 26Hoenlein Malcolmother27,322
Jan 1, 26LOBELL J JAYother27,322
Oct 1, 25Jin Davidother2,711
Apr 1, 25Jin Davidother5,000

Our FBIO Coverage

We haven't published any research on FBIO yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate FBIO Report →

Similar Companies